0001213900-26-056576
SEC filingFY2025 delivered $399.9M revenue but suffered -$130.9M net loss and -$149.5M free cash flow due to operating losses and cash burn, as growth investments outpaced profitability amid inventory management challenges.
POMDOCTOR Ltd's FY2025 results show revenue scaling to $399.9M, yet profitability eroded sharply with gross profit at $52.3M (13.1% margin) and operating income plunging to -$118.6M (-29.7% margin). This reflects the challenges of high-volume drug distribution, where maintaining optimal inventory levels is critical. Excess inventory risks write-downs, product expiration, or higher holding costs, directly impacting liquidity and margins, while suboptimal levels could spike operating costs or cause unfulfilled orders—both threatening business prospects. The company's AI-assisted central inventory system analyzes warehouse location and supply status to optimize dispatching, aiming to cut logistics costs and boost satisfaction, but execution strains contributed to the operating shortfall.
Net income deepened to -$130.9M (diluted EPS -$21.96), underscoring how growth investments outpaced revenue gains. Cash generation deteriorated with operating cash flow at -$148.5M and free cash flow at -$149.5M after minimal $1.0M capex, primarily from working capital swings tied to inventory dynamics. These pressures highlight the capital intensity of scaling distribution amid related-party exposures, where unsecured, non-interest-bearing advances and demand-due balances to related parties add liquidity risks without interest offsets.